{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T17:50:17Z","timestamp":1792691417748,"version":"4.5.0"},"reference-count":80,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T00:00:00Z","timestamp":1683244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nutrients"],"abstract":"<jats:p>The serum low density lipoprotein cholesterol (LDL-C) concentration is the dominant clinical parameter to judge a patient\u2019s risk of developing cardiovascular disease (CVD). Recent evidence supports the theory that cholesterol in serum triglyceride-rich lipoproteins (TRLs) contributes significantly to the atherogenic risk, independent of LDL-C. Therefore, combined analysis of both targets and adequate treatment may improve prevention of CVD. The validity of TRL-C calculation is solely dependent on the accuracy of the LDL-C measurement. Direct measurement of serum LDL- C is more accurate than established estimation procedures based upon Friedewald, Martin\u2013Hopkins, or Sampson equations. TRL-C can be easily calculated as total C minus high density lipoprotein C (HDL-C) minus LDL-C. Enhanced serum LDL-C or TRL-C concentrations require different therapeutic approaches to lower the atherogenic lipoprotein C. This review describes the different atherogenic lipoproteins and their possible analytical properties and limitations.<\/jats:p>","DOI":"10.3390\/nu15092202","type":"journal-article","created":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T02:03:31Z","timestamp":1683511411000},"page":"2202","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Measurement of Serum Low Density Lipoprotein Cholesterol and Triglyceride-Rich Remnant Cholesterol as Independent Predictors of Atherosclerotic Cardiovascular Disease: Possibilities and Limitations"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7941-8308","authenticated-orcid":false,"given":"Dieter","family":"L\u00fctjohann","sequence":"first","affiliation":[{"name":"Institute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, 53127 Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Ulrich","family":"Kl\u00f6r","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III, University of Gie\u00dfen, 35392 Gie\u00dfen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frans","family":"Stellaard","sequence":"additional","affiliation":[{"name":"Institute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, 53127 Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,5,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s00392-022-02108-w","article-title":"Hypercholesterolemia diagnosis, treatment patterns and target achievement in patients with acute coronary syndromes in Germany","volume":"112","author":"Gitt","year":"2023","journal-title":"Clin. Res. Cardiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/0002-9149(85)90296-6","article-title":"Coronary risk factors and their pathway of action through coronary raised lesions, coronary stenoses and coronary death. Multivariate statistical analysis of an autopsy series: The Oslo Study","volume":"55","author":"Holme","year":"1985","journal-title":"Am. J. Cardiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"85","DOI":"10.7326\/0003-4819-90-1-85","article-title":"Cholesterol in the prediction of atherosclerotic disease. New perspectives based on the Framingham study","volume":"90","author":"Kannel","year":"1979","journal-title":"Ann. Intern. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJM198601163140302","article-title":"Relation of serum lipoprotein levels and systolic blood pressure to early atherosclerosis. The Bogalusa Heart Study","volume":"314","author":"Newman","year":"1986","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/0014-4800(89)90043-9","article-title":"Low-density lipoproteins isolated from the blood of patients with coronary heart disease induce the accumulation of lipids in human aortic cells","volume":"50","author":"Tertov","year":"1989","journal-title":"Exp. Mol. Pathol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1024\/0301-1526\/a000451","article-title":"Moving beyond the \u201cLDL hypothesis\u201d","volume":"44","author":"Werner","year":"2015","journal-title":"Vasa"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1159\/000057673","article-title":"New advances in lipid-modifying therapies for reducing cardiovascular risk","volume":"97","author":"Bruckert","year":"2002","journal-title":"Cardiology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s12170-022-00694-y","article-title":"New Strategies for Lowering Low Density Lipoprotein Cholesterol for Cardiovascular Disease Prevention","volume":"16","author":"Gaine","year":"2022","journal-title":"Curr. Cardiovasc. Risk Rep."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Makhmudova, U., Samadifar, B., Maloku, A., Haxhikadrija, P., Geiling, J.A., Romer, R., Lauer, B., Mobius-Winkler, S., Otto, S., and Schulze, P.C. (2023). Intensive lipid-lowering therapy for early achievement of guideline-recommended LDL-cholesterol levels in patients with ST-elevation myocardial infarction (\u201cJena auf Ziel\u201d). Clin. Res. Cardiol., Online ahead of print.","DOI":"10.1007\/s00392-022-02147-3"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/j.amjmed.2022.06.018","article-title":"Inter-Individual Variability in Lipid Response: A Narrative Review","volume":"135","author":"Patnaik","year":"2022","journal-title":"Am. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Sun, L., Wolska, A., Amar, M., Zubiran, R., and Remaley, A.T. (2023). Approach to the Patient with a Suboptimal Statin Response: Causes and Algorithm for Clinical Management. J. Clin. Endocrinol. Metab., Online ahead of print.","DOI":"10.1210\/clinem\/dgad153"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1161\/CIRCULATIONAHA.122.061620","article-title":"Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease","volume":"146","author":"Giugliano","year":"2022","journal-title":"Circulation"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Laufs, U., Birkenfeld, A.L., Fraass, U., Hohenstein, B., Siegert, C., Klotsche, J., Steinhagen-Thiessen, E., Pittrow, D., Dexl, S., and Salmen, S. (2022). Novel Insights into the Management of Patients with Very High Cardiovascular Risk Eligible for PCSK9 Inhibitor Treatment: Baseline Findings from the PERI-DYS Study. Cardiovasc. Drugs Ther., Online ahead of print.","DOI":"10.1093\/eurheartj\/ehab724.2562"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Kumari, A., Kristensen, K.K., Ploug, M., and Winther, A.L. (2021). The Importance of Lipoprotein Lipase Regulation in Atherosclerosis. Biomedicines, 9.","DOI":"10.3390\/biomedicines9070782"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.ecl.2022.02.008","article-title":"Lipid and Lipoprotein Metabolism","volume":"51","author":"Feingold","year":"2022","journal-title":"Endocrinol. Metab. Clin. N. Am."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Jansen, M., and Contini, C. (2022). LDL retention time in plasma can be -based on causation- estimated by the lipid composition of LDL and other lipoproteins. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0272050"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Kuklenyik, Z., Jones, J.I., Gardner, M.S., Schieltz, D.M., Parks, B.A., Toth, C.A., Rees, J.C., Andrews, M.L., Carter, K., and Lehtikoski, A.K. (2018). Core lipid, surface lipid and apolipoprotein composition analysis of lipoprotein particles as a function of particle size in one workflow integrating asymmetric flow field-flow fractionation and liquid chromatography-tandem mass spectrometry. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0194797"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1194\/jlr.RA120000691","article-title":"The lipid transfer properties of CETP define the concentration and composition of plasma lipoproteins","volume":"61","author":"Morton","year":"2020","journal-title":"J. Lipid Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/joim.12877","article-title":"Investigation of human apoB48 metabolism using a new, integrated non-steady-state model of apoB48 and apoB100 kinetics","volume":"285","author":"Bjornson","year":"2019","journal-title":"J. Intern. Med."},{"key":"ref_20","first-page":"168","article-title":"Postprandial Dyslipidemia: Pathophysiology and Cardiovascular Disease Risk Assessment","volume":"28","author":"Higgins","year":"2017","journal-title":"EJIFCC"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/MOL.0000000000000578","article-title":"Chylomicron retention disease: Genetics, biochemistry, and clinical spectrum","volume":"30","author":"Levy","year":"2019","journal-title":"Curr. Opin. Lipidol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"796","DOI":"10.3389\/fphys.2020.00796","article-title":"ApoB48 as an Efficient Regulator of Intestinal Lipid Transport","volume":"11","author":"Lo","year":"2020","journal-title":"Front. Physiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/MOL.0000000000000429","article-title":"Remnant lipoproteins","volume":"28","author":"Varbo","year":"2017","journal-title":"Curr. Opin. Lipidol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/eurheartj\/ehz785","article-title":"Clinical review on triglycerides","volume":"41","author":"Laufs","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1177\/00045632221102767","article-title":"Calculated small dense LDL-cholesterol and its correlation with the atherogenic index of plasma","volume":"59","author":"Tomo","year":"2022","journal-title":"Ann. Clin. Biochem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1097\/00041433-200012000-00008","article-title":"Remnant lipoproteins as therapeutic targets","volume":"11","author":"Havel","year":"2000","journal-title":"Curr. Opin. Lipidol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.amjcard.2007.11.046","article-title":"Relative atherogenicity and predictive value of non-high-density lipoprotein cholesterol for coronary heart disease","volume":"101","author":"Miller","year":"2008","journal-title":"Am. J. Cardiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1001\/jamacardio.2019.3780","article-title":"Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review","volume":"4","author":"Sniderman","year":"2019","journal-title":"JAMA Cardiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/MED.0000000000000389","article-title":"Discordance between lipoprotein particle number and cholesterol content: An update","volume":"25","author":"Cantey","year":"2018","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"762","DOI":"10.4065\/mcp.2011.0128","article-title":"Opening a new lipid \u201capo-thecary\u201d: Incorporating apolipoproteins as potential risk factors and treatment targets to reduce cardiovascular risk","volume":"86","author":"Jacobson","year":"2011","journal-title":"Mayo Clin. Proc."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"101658","DOI":"10.1016\/j.beem.2022.101658","article-title":"Approach to patients with elevated low-density lipoprotein cholesterol levels","volume":"37","author":"Feingold","year":"2023","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Liu, H., Li, J., Liu, F., Huang, K., Cao, J., Chen, S., Li, H., Shen, C., Hu, D., and Huang, J. (Eur. J. Prev. Cardiol., 2023). Efficacy and safety of low levels of low-density lipoprotein cholesterol: Trans-ancestry linear and non-linear Mendelian randomization analyses, Eur. J. Prev. Cardiol., Online ahead of print.","DOI":"10.1093\/eurjpc\/zwad111"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1093\/clinchem\/hvad012","article-title":"The Present and Future of Lipid Testing in Cardiovascular Risk Assessment","volume":"69","author":"Higgins","year":"2023","journal-title":"Clin. Chem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/0021-9150(84)90074-1","article-title":"Cholesteryl ester transfer activity. Localization and role in distribution of cholesteryl ester among lipoproteins in man","volume":"50","author":"Groener","year":"1984","journal-title":"Atherosclerosis"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Nelson, A.J., Sniderman, A.D., Ditmarsch, M., Dicklin, M.R., Nicholls, S.J., Davidson, M.H., and Kastelein, J.J.P. (2022). Cholesteryl Ester Transfer Protein Inhibition Reduces Major Adverse Cardiovascular Events by Lowering Apolipoprotein B Levels. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23169417"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jacbts.2021.09.011","article-title":"Interplay of Low-Density Lipoprotein Receptors, LRPs, and Lipoproteins in Pulmonary Hypertension","volume":"7","author":"Calvier","year":"2022","journal-title":"JACC Basic Transl. Sci."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1042\/bj2680685","article-title":"Evidence for reverse cholesterol transport in vivo from liver endothelial cells to parenchymal cells and bile by high-density lipoprotein","volume":"268","author":"Bakkeren","year":"1990","journal-title":"Biochem. J."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1126\/science.204996","article-title":"Preferential utilization of free cholesterol from high-density lipoproteins for biliary cholesterol secretion in man","volume":"200","author":"Schwartz","year":"1978","journal-title":"Science"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1042\/bj2800359","article-title":"Selective uptake of cholesteryl esters from apolipoprotein-E-free high-density lipoproteins by rat parenchymal cells in vivo is efficiently coupled to bile acid synthesis","volume":"280","author":"Pieters","year":"1991","journal-title":"Biochem. J."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jacl.2010.03.005","article-title":"Why is non-high-density lipoprotein cholesterol a better marker of the risk of vascular disease than low-density lipoprotein cholesterol?","volume":"4","author":"Sniderman","year":"2010","journal-title":"J. Clin. Lipidol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.atherosclerosis.2019.05.011","article-title":"A third of nonfasting plasma cholesterol is in remnant lipoproteins: Lipoprotein subclass profiling in 9293 individuals","volume":"286","author":"Balling","year":"2019","journal-title":"Atherosclerosis"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jacl.2010.03.004","article-title":"Should we use apoB for risk assessment and as a target for treatment?","volume":"4","author":"Brown","year":"2010","journal-title":"J. Clin. Lipidol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s11886-020-01323-z","article-title":"Non-HDL Cholesterol or apoB: Which to Prefer as a Target for the Prevention of Atherosclerotic Cardiovascular Disease?","volume":"22","author":"Langlois","year":"2020","journal-title":"Curr. Cardiol. Rep."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0950-351X(87)80022-8","article-title":"Lipoproteins and atherosclerosis","volume":"1","author":"Babiak","year":"1987","journal-title":"Baillieres Clin. Endocrinol. Metab."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0009-8981(94)90274-7","article-title":"Separation of lipoprotein fractions by ultracentrifugation: Investigation of analytical recovery with sequential flotation and density gradient procedures","volume":"230","author":"Potts","year":"1994","journal-title":"Clin. Chim. Acta"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/0003-2697(75)90488-1","article-title":"Separation of plasma lipoproteins by density-gradient ultracentrifugation","volume":"65","author":"Redgrave","year":"1975","journal-title":"Anal. Biochem."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/PL00020550","article-title":"Method for quantitating cholesterol in subfractions of serum lipoproteins separated by gradient gel electrophoresis","volume":"26","author":"Cheng","year":"1988","journal-title":"Biochem. Genet."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"II21","DOI":"10.1002\/clc.4960221405","article-title":"Measurement of triglyceride-rich lipoproteins by nuclear magnetic resonance spectroscopy","volume":"22","author":"Otvos","year":"1999","journal-title":"Clin. Cardiol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.5551\/jat.RV17037","article-title":"Innovatively Established Analysis Method for Lipoprotein Profiles Based on High-Performance Anion-Exchange Liquid Chromatography","volume":"26","author":"Hirowatari","year":"2019","journal-title":"J. Atheroscler. Thromb."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","article-title":"Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge","volume":"18","author":"Friedewald","year":"1972","journal-title":"Clin. Chem."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/MOL.0000000000000833","article-title":"How should low-density lipoprotein cholesterol be calculated in 2022?","volume":"33","author":"Martins","year":"2022","journal-title":"Curr. Opin. Lipidol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"515","DOI":"10.2174\/1570161117666190503123911","article-title":"Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Narrative Review","volume":"17","author":"Kolovou","year":"2019","journal-title":"Curr. Vasc. Pharmacol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"498","DOI":"10.2174\/1570161117666190507110519","article-title":"Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Main Text","volume":"17","author":"Kolovou","year":"2019","journal-title":"Curr. Vasc. Pharmacol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"386","DOI":"10.21037\/atm-20-3962","article-title":"The difference between fasting and non-fasting lipid measurements is not related to statin treatment","volume":"9","author":"Liu","year":"2021","journal-title":"Ann. Transl. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.cca.2016.12.011","article-title":"Triglyceride content in remnant lipoproteins is significantly increased after food intake and is associated with plasma lipoprotein lipase","volume":"465","author":"Nakajima","year":"2017","journal-title":"Clin. Chim. Acta"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.bbalip.2016.04.012","article-title":"Recent discoveries on absorption of dietary fat: Presence, synthesis, and metabolism of cytoplasmic lipid droplets within enterocytes","volume":"1861","author":"Hung","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1001\/jama.2013.280532","article-title":"Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile","volume":"310","author":"Martin","year":"2013","journal-title":"JAMA"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1001\/jamacardio.2020.0013","article-title":"A New Equation for Calculation of Low-Density Lipoprotein Cholesterol in Patients With Normolipidemia and\/or Hypertriglyceridemia","volume":"5","author":"Sampson","year":"2020","journal-title":"JAMA Cardiol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1373\/clinchem.2009.142810","article-title":"Seven direct methods for measuring HDL and LDL cholesterol compared with ultracentrifugation reference measurement procedures","volume":"56","author":"Miller","year":"2010","journal-title":"Clin. Chem."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0021-9150(95)05791-9","article-title":"Triglyceride enriched lipoprotein particles correlate with the severity of coronary artery disease","volume":"122","author":"Koren","year":"1996","journal-title":"Atherosclerosis"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.amjcard.2022.09.022","article-title":"Associations of Cardiorespiratory Fitness With Estimated Remnant Cholesterol and Non-High-Density Lipoprotein Cholesterol in Healthy Men","volume":"186","author":"Jae","year":"2023","journal-title":"Am. J. Cardiol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"951523","DOI":"10.3389\/fcvm.2022.951523","article-title":"Prognostic value of remnant cholesterol in patients with coronary heart disease: A systematic review and meta-analysis of cohort studies","volume":"9","author":"Tian","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Yang, J., Wang, Y., Xi, Z., Ma, Y., Shao, C., Wang, W., and Tang, Y.D. (2022). Remnant-Like Particle Cholesterol and the Risk of Major Adverse Cardiovascular Events: A Systematic Review and Meta-Analysis. J. Cardiovasc. Dev. Dis., 9.","DOI":"10.3390\/jcdd9120452"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"575","DOI":"10.3803\/EnM.2022.402","article-title":"Lipoprotein Lipase: Is It a Magic Target for the Treatment of Hypertriglyceridemia","volume":"37","author":"Moon","year":"2022","journal-title":"Endocrinol. Metab."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1007\/s11033-021-06248-6","article-title":"ANGPLT3 in cardio-metabolic disorders","volume":"48","author":"Su","year":"2021","journal-title":"Mol. Biol. Rep."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"883","DOI":"10.5551\/jat.RV17054","article-title":"Current Diagnosis and Management of Primary Chylomicronemia","volume":"28","author":"Okazaki","year":"2021","journal-title":"J. Atheroscler. Thromb."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e3473","DOI":"10.1210\/clinem\/dgab360","article-title":"Rare Variants in Triglycerides-Related Genes Increase Pancreatitis Risk in Multifactorial Chylomicronemia Syndrome","volume":"106","author":"Paquette","year":"2021","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.cca.2022.10.003","article-title":"Comparability of calculated LDL-C with directly measured LDL-C in selected paediatric and adult cohorts","volume":"537","author":"Steyn","year":"2022","journal-title":"Clin. Chim. Acta"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"4833","DOI":"10.1093\/eurheartj\/ehab293","article-title":"Directly measured vs. calculated remnant cholesterol identifies additional overlooked individuals in the general population at higher risk of myocardial infarction","volume":"42","author":"Varbo","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta22680","article-title":"Bariatric surgery, lifestyle interventions and orlistat for severe obesity: The REBALANCE mixed-methods systematic review and economic evaluation","volume":"22","author":"Avenell","year":"2018","journal-title":"Health Technol. Assess."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"119115","DOI":"10.1016\/j.lfs.2021.119115","article-title":"Pancreatic lipase inhibitors: The road voyaged and successes","volume":"271","author":"Kumar","year":"2021","journal-title":"Life Sci."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"174","DOI":"10.2174\/0929867326666190124121725","article-title":"Obesity Therapy: How and Why?","volume":"27","author":"Paccosi","year":"2020","journal-title":"Curr. Med. Chem."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.atherosclerosis.2017.03.032","article-title":"Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor alpha modulator (SPPARMalpha), in combination with statin treatment: Two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia","volume":"261","author":"Arai","year":"2017","journal-title":"Atherosclerosis"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.tcm.2019.04.009","article-title":"Icosapent ethyl: Where will it fit into guideline-based medical therapy for high risk atherosclerotic cardiovascular disease?","volume":"30","author":"Orringer","year":"2020","journal-title":"Trends Cardiovasc. Med."},{"key":"ref_75","first-page":"9464733","article-title":"Real-World Evidence Evaluation on the Lipid Profile, Therapeutic Goals, and Safety of the Fixed-Dose Combination of Rosuvastatin\/Ezetimibe (Trezete(R)) in Dyslipidemia Patients","volume":"2022","year":"2022","journal-title":"Cardiol. Res. Pract."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1194\/jlr.P900004-JLR200","article-title":"Changes in cholesterol absorption and cholesterol synthesis caused by ezetimibe and\/or simvastatin in men","volume":"50","author":"Sudhop","year":"2009","journal-title":"J. Lipid Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.pathol.2018.11.006","article-title":"Non-HDL-cholesterol and apolipoprotein B compared with LDL-cholesterol in atherosclerotic cardiovascular disease risk assessment","volume":"51","author":"Carr","year":"2019","journal-title":"Pathology"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.jacc.2021.01.027","article-title":"Apolipoprotein B and Non-HDL Cholesterol Better Reflect Residual Risk Than LDL Cholesterol in Statin-Treated Patients","volume":"77","author":"Johannesen","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.atherosclerosis.2012.08.022","article-title":"A multicenter study on the precision and accuracy of homogeneous assays for LDL-cholesterol: Comparison with a beta-quantification method using fresh serum obtained from non-diseased and diseased subjects","volume":"225","author":"Miida","year":"2012","journal-title":"Atherosclerosis"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1373\/clinchem.2019.307678","article-title":"LDL Cholesterol: What Is the Best Way to Measure It?","volume":"65","author":"Wolska","year":"2019","journal-title":"Clin. Chem."}],"container-title":["Nutrients"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6643\/15\/9\/2202\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:29:58Z","timestamp":1760124598000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6643\/15\/9\/2202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,5]]},"references-count":80,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["nu15092202"],"URL":"https:\/\/doi.org\/10.3390\/nu15092202","relation":{},"ISSN":["2072-6643"],"issn-type":[{"value":"2072-6643","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,5]]}}}